Literature DB >> 9126894

Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

L Palma1, P Celli, C Franco, L Cervoni, G Cantore.   

Abstract

To contribute to a better understanding of the prognostic differences between atypical and malignant meningiomas as defined by the World Health Organization (WHO) and the influence of the grade of initial surgical excision on postoperative course, 42 cases of atypical and 29 of malignant meningioma were studied, along with long-term follow up. The two groups were compared with respect to long-term survival, recurrence-free survival, and median time to recurrence. The prognostic significance of the Simpson grade of surgical resection and tumor location was also considered. Survival at 5 and 10 years was recorded in 95% and 79%, respectively, of patients with atypical meningioma and in 64.3% and 34.5% of patients with malignant meningioma (p = 0.001). Recurrence-free survival and median time to recurrence were also significantly longer in patients with atypical than in those with malignant meningiomas: 11.9 versus 2 years (p = 0.001) and 5 versus 2 years (p < 0.0041), respectively. Six (26%) of the 23 recurring atypical meningiomas became malignant. Simpson Grade I resection and location in the cerebral convexity, which were closely related, were found to be associated with a significantly better clinical course in the entire series (p < or = 0.0016). Patients with atypical meningiomas fared better than those with malignant meningiomas after incomplete surgical excision (Simpson Grades II-III), but the difference was not statistically significant. Multivariate analysis using the Cox model indicated that radical extirpation (Simpson Grade I vs. II-III) and histological findings (atypical meningioma vs. malignant meningioma) were significantly related to prolonged survival (p < 0.0003 and p < 0.0388, respectively). In conclusion, the current study shows that for most patients with atypical meningioma the prognosis was less severe than for those with malignant meningioma, but the risk of a downhill course resulting from malignancy after incomplete resection and recurrence was not negligible (26%). In addition, the WHO classification was found to be inadequate for a minority of the atypical meningioma cases, which currently have the same unfavorable course as cases of malignant meningioma. The results also indicate that objective Simpson Grade I extirpation of convexity meningiomas can be successful despite histological findings of malignancy.

Entities:  

Mesh:

Year:  1997        PMID: 9126894     DOI: 10.3171/jns.1997.86.5.0793

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  56 in total

1.  Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.

Authors:  S Ozaki; T Nishizaki; H Ito; K Sasaki
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification.

Authors:  M Simon; J Boström; P Koch; J Schramm
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

3.  The diagnostic value of using combined MR diffusion tensor imaging parameters to differentiate between low- and high-grade meningioma.

Authors:  Kerim Aslan; Hediye Pinar Gunbey; Leman Tomak; Lutfi Incesu
Journal:  Br J Radiol       Date:  2018-05-31       Impact factor: 3.039

4.  Atypical and anaplastic meningioma: outcomes in a population based study.

Authors:  T Garzon-Muvdi; W Yang; M Lim; H Brem; J Huang
Journal:  J Neurooncol       Date:  2017-04-20       Impact factor: 4.130

5.  NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.

Authors:  John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

6.  Role of external beam radiotherapy in the treatment of relapsing meningioma.

Authors:  M Buglione; B De Bari; F Trevisan; P Ghirardelli; S Pedretti; L Triggiani; S M Magrini
Journal:  Med Oncol       Date:  2014-02-07       Impact factor: 3.064

7.  Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment.

Authors:  Rossella Di Franco; Valentina Borzillo; Vincenzo Ravo; Sara Falivene; Francesco Jacopo Romano; Matteo Muto; Fabrizio Cammarota; Giuseppe Totaro; Gianluca Ametrano; Sabrina Rossetti; Carla Cavaliere; Carmine D' Aniello; Gelsomina Iovane; Maria Assunta Porricelli; Massimiliano Berretta; Gerardo Botti; Luigi Starace; Enrico La Salvia; Gaetano Facchini; Paolo Muto
Journal:  Neuroradiol J       Date:  2017-12-05

8.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

9.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

10.  Extent of resection and survival outcomes in World Health Organization grade II meningiomas.

Authors:  Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos
Journal:  J Neurooncol       Date:  2020-11-17       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.